Merck (MRK) Capital Expenditures (2009 - 2026)

Merck (MRK) has 18 years of Capital Expenditures data on file, last reported at $991.0 million in Q1 2026.

• Quarterly Capital Expenditures fell 25.38% year-over-year to $991.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 billion (down 1.67% YoY) and the FY2025 annual result came in at $4.1 billion, up 21.95% from the prior year.
• Capital Expenditures fell to $991.0 million in Q1 2026 per MRK's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.3 billion in Q1 2025 and bottomed at $764.0 million in Q2 2025.
• The 5-year median for Capital Expenditures is $987.0 million (2025), against an average of $983.9 million.
• The widest annual swing landed in 2025, when Capital Expenditures surged 54.24%; it then retreated 25.38% in 2026.
• Tracing MRK's Capital Expenditures over 5 years: stood at $1.1 billion in 2022, then fell by 13.93% to $989.0 million in 2023, then declined by 5.26% to $937.0 million in 2024, then increased by 10.25% to $1.0 billion in 2025, then slipped by 4.07% to $991.0 million in 2026.
• Per Business Quant, the three latest MRK Capital Expenditures figures stand at $991.0 million (Q1 2026), $1.0 billion (Q4 2025), and $987.0 million (Q3 2025).

Peer Comparison